Asset profile
Divalproex sodium (Depakote ER)
Unknown / undisclosed
Evidence outlook
Approved: Migraine
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
53 competitors in this universe: 1 direct rival (same mechanism and indication), 1 same-class, 51 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Divalproex Sodium (Depakote ER): this drug | Approved | — | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | ||
| Valproate | Approved | Small molecule | GABAergic neurotransmission | ||
| Almotriptan (Axert) | Approved | Small molecule | — | ||
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | — | ||
| Atogepant (Qulipta) | Approved | Small molecule | — | ||
| Celecoxib (Elyxyb) | Approved | Small molecule | — | ||
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | ||
| Dihydroergotamine (Atzumi) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Brekiya) | Approved | — | — | ||
| Dihydroergotamine Mesylate (D.H.E. 45) | Approved | — | — | ||
| Dihydroergotamine Mesylate (Migranal) | Approved | — | — | ||
| Eletriptan (Relpax) | Approved | Small molecule | — | ||
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | — | ||
| Erenumab (Aimovig) | Approved | Monoclonal antibody | — | ||
| Ergotamine / Caffeine (Cafergot) | Approved | — | — |
…and 38 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.